Scimitar Equity, LLC is an independent equity research firm focused on providing value-added intelligence and insightful investment conclusions on emerging companies demonstrating real progress toward their vision while meeting quarterly expectation.
IntelliCell (OTCQB: SVFC) filed Patent Application
Filed Patent Application for its proprietary Method of Manufacturing Stromal Vascular Fraction Cells
OTCQB: SVFC (PINKSHEETS: SVFC.PK) filed its patent application with the USPTO … that will claim priority … to its provisional US patent serial #61/427, 221 that was filed on 12/27/10.
- The title of the patent application is “Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived There from Obtained from Adipose Tissue and use Thereof”.
The Bottom Line: The … patent application … covers the methods of manufacturing using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within the adipose tissue, thereby obtaining multi-potent, mesenchymal or stromal vascular fractions for use in human subjects. These methods do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased number of cells which constitute the multi-potent, mesenchymal or stromal vascular fractions (about 10 folds greater than methods which use collagenase to isolate these cells).
Register here to be notified of future Scimitar Equity articles.
